ID: ALA2165613

Max Phase: Preclinical

Molecular Formula: C16H14N2O2

Molecular Weight: 266.30

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=c1cc(COc2cccc(-c3ccccc3)c2)[nH][nH]1

Standard InChI:  InChI=1S/C16H14N2O2/c19-16-10-14(17-18-16)11-20-15-8-4-7-13(9-15)12-5-2-1-3-6-12/h1-10H,11H2,(H2,17,18,19)

Standard InChI Key:  CWGBCGMPIOFCCY-UHFFFAOYSA-N

Associated Targets(Human)

Superoxide dismutase 173 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 266.30Molecular Weight (Monoisotopic): 266.1055AlogP: 2.95#Rotatable Bonds: 4
Polar Surface Area: 57.88Molecular Species: NEUTRALHBA: 2HBD: 2
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 7.56CX Basic pKa: CX LogP: 2.33CX LogD: 2.12
Aromatic Rings: 3Heavy Atoms: 20QED Weighted: 0.76Np Likeness Score: -0.69

References

1. Chen T, Benmohamed R, Kim J, Smith K, Amante D, Morimoto RI, Kirsch DR, Ferrante RJ, Silverman RB..  (2012)  ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.,  55  (1): [PMID:22191331] [10.1021/jm2014277]

Source